Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

[1]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[2]  Sunita Ghosh,et al.  A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[3]  M. Buyse,et al.  Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Burke,et al.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Hilsenbeck,et al.  Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Schoenfeld,et al.  Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Abrams,et al.  Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study , 2011, BMC medical research methodology.

[8]  R. Motzer,et al.  Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial. , 2010 .

[9]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[12]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Sternberg,et al.  A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Soulières.  Review of guidelines on the treatment of metastatic renal cell carcinoma , 2009, Current Oncology.

[16]  B. Rini,et al.  A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer , 2009, Cancer.

[17]  R. Motzer,et al.  Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. , 2008, Clinical genitourinary cancer.

[18]  S. Stein,et al.  Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.

[19]  A. Ravaud,et al.  Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer , 2008, Clinical Cancer Research.

[20]  J. Knox.  Progression-free survival as endpoint in metastatic RCC? , 2008, The Lancet.

[21]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[22]  B. Freidlin,et al.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Amato,et al.  Interferon-&agr; in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial , 2008, Anti-cancer drugs.

[24]  Chris Coppin,et al.  Immunotherapy for renal cell cancer in the era of targeted therapy , 2008, Expert review of anticancer therapy.

[25]  R. Figlin,et al.  Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .

[26]  T. Wilt,et al.  Targeted therapy for advanced renal cell carcinoma. , 2008, The Cochrane database of systematic reviews.

[27]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Sargent,et al.  Assessing the measure of a new drug: is survival the only thing that matters? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Lilford,et al.  The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. , 2008, Cancer letters.

[30]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[31]  A. Ravaud,et al.  Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis , 2007, Cancer.

[32]  D. Sargent,et al.  Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[34]  L. Siu,et al.  Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Wilding,et al.  Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib , 2007 .

[37]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[38]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[39]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[40]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[41]  P. Thall,et al.  Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. , 2006, Cancer.

[42]  N. Freemantle,et al.  Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. , 2006, The Lancet. Oncology.

[43]  H. Heinzer,et al.  Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) , 2006, British Journal of Cancer.

[44]  N. Thatcher,et al.  Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma , 2005, British Journal of Cancer.

[45]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Fosså,et al.  Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Loening,et al.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  K. Carroll,et al.  On the use and utility of the Weibull model in the analysis of survival data. , 2003, Controlled clinical trials.

[50]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[51]  C. Stief,et al.  Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinoma , 2002, Cancer.

[52]  M. Gramatzki,et al.  IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial , 2001, British Journal of Cancer.

[53]  C. Tournigand,et al.  Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma , 2001, Cancer.

[54]  J. Rossi,et al.  Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  L. Schwartz,et al.  Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  T. Tammela,et al.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Gareth Griffiths,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.

[58]  P. Fayers,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial , 1999 .

[59]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[60]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[61]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[62]  Jonathan E. Dickerson,et al.  Supplementary webappendix , 2009 .

[63]  J. Thompson Coon,et al.  Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. , 2010, Health technology assessment.

[64]  R. Kelly,et al.  Axitinib (AG-013736). , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[65]  M. Atkins,et al.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  J. Fine,et al.  Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890) , 2003, Medical oncology.

[67]  A. Eggermont,et al.  High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. , 1997, Journal of immunotherapy.